How can precision medicine approaches stratify AD patients into mechanistically distinct subtypes for targeted therapy selection?

Current trial designs treat AD as monolithic despite evidence of heterogeneity. There are no ongoing studies attempting to match patients to therapies based on underlying pathogenic dominance patterns.